1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
Ghiringhelli, F., Felip, E., Zer, A., Greillier, L., Greystoke, A., Al-Sakaff, N., Helms, H-J., Pintoffl, J.P., Rahalkar, S., Lim, F.L., Cho, B.C.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Neal, J.W., Lim, F.L., Aix, S.P., Viteri, S., Santoro, A., Spencer, K., Fang, B., Khrizman, P., Kim, J., Subbiah, V., Sudhagoni, R., Samaraweera, L., Andrianova, L., Felip, E.
Published in Journal of thoracic oncology (01.09.2022)
Published in Journal of thoracic oncology (01.09.2022)
Get full text
Journal Article
EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Garon, E.B., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Kim, S.-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C.-T., Araujo, L.H., Saito, H., Reinmuth, N., Kohlmann, M., Shi, X., Mann, H., Peters, S., Mok, T., Johnson, M.L.
Published in Journal of thoracic oncology (01.09.2022)
Published in Journal of thoracic oncology (01.09.2022)
Get full text
Journal Article
LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Johnson, M., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E., Mok, T.S.K.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Garon, E.B., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Trukhin, D., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Reinmuth, N., Medic, N., Mann, H., Shi, X., Peters, S., Mok, T.S.K., Johnson, M.
Published in Annals of oncology (01.04.2022)
Published in Annals of oncology (01.04.2022)
Get full text
Journal Article
12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
Reinmuth, N., Cho, B.C., Luft, A., Alexander, J.A. Alatorre, Geater, S. Lucien, Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Barrett, K., Lowery, C., Tattersfield, R., Peters, S., Garon, E.B., Mok, T.S.K., Johnson, M.L.
Published in Journal of thoracic oncology (01.04.2023)
Published in Journal of thoracic oncology (01.04.2023)
Get full text
Journal Article
Lower polyunsaturated fatty acid levels and FADS2 expression in adult compared to neonatal keratinocytes are associated with FADS2 promotor hypermethylation
Pararasa, C., Messenger, D.J., Barrett, K.E., Hyliands, D., Talbot, D., Fowler, M.I., Kawatra, T., Gunn, D.A., Lim, F.L., Wainwright, L.J., Jenkins, G., Griffiths, H.R.
Published in Biochemical and biophysical research communications (23.04.2022)
Published in Biochemical and biophysical research communications (23.04.2022)
Get full text
Journal Article
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
Peters, S., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Kim, S.-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C.-T., Araujo, L.H., Saito, H., Reinmuth, N., Stewart, R., Lai, Z., Doake, R., Krug, L., Garon, E.B., Mok, T., Johnson, M.L.
Published in Journal of thoracic oncology (01.09.2022)
Published in Journal of thoracic oncology (01.09.2022)
Get full text
Journal Article
Matrix Metalloproteinase 12 is an Indicator of Intervertebral Disc Degeneration Co-expressed with Fibrotic Markers
Lv, Feng-Juan, Ph.D, Peng, Yan, MPhil, Lim, Foon Lian, Ph.D, Sun, Yi, Ph.D, Lv, Minmin, MPhil, Zhou, Lixiong, Ph.D, Wang, Hua, Ph.D, Zheng, Zhaomin, M.D, Cheung, Kenneth MC., M.D, Leung, Victor YL., Dr
Published in Osteoarthritis and cartilage (01.10.2016)
Published in Osteoarthritis and cartilage (01.10.2016)
Get full text
Journal Article
1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Felip, E., Lim, F.L., Johnson, M., O'Brien, M., Barlesi, F., Mazieres, J., Solomon, B., Moreno, V., Boni, V., Swalduz, A., Goldberg, S., Keam, B., Allen, S., Helms, H-J., Shemesh, C., Pintoffl, J., Al-Sakaff, N., Bailey, L., Sayyed, P., Cho, B.C.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study
Peters, S., Cho, B.C., Luft, A., Alexander, J.A. Alatorre, Geater, S. Lucien, Laktionov, K., Trukhin, D., Kim, S.-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Szadkowski, L., Lowery, C., Garon, E.B., Mok, T.S.K., Johnson, M.L.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article
Current Knowledge and Attitudes About Organ Donation and Transplantation Among Chinese University Students
Chen, J.X., Zhang, T.M., Lim, F.L., Wu, H.C., Lei, T.F., Yeong, P.K., Xia, S.J.
Published in Transplantation proceedings (01.11.2006)
Published in Transplantation proceedings (01.11.2006)
Get full text
Journal Article